Real-World Demographics and Clinical Characteristics of Multiple Myeloma Patients in a Colombian HMO During 2015-2023
Author(s)
Leonardo Jose Enciso Olivera, MD1, Farley Gonzalez, MSc1, Juan Manuel Reyes Sanchez, MSc2, Luz E. Perez Jaramillo, Sr., MSc1, Jair A. Arciniegas, MSc2, Carlos Bello, Pharm1, Andreina J. Alamo, BSc2, Mónica García, MSc2, Brigitte Alejandra Alarcon, MD2, Jhon E. Bolaños, MSc, MD1;
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To measure the demographic and clinical characteristics in multiple myeloma (MM) patients from a Colombian Health Maintenance Organization between 2015-2023.
METHODS: A retrospective, descriptive and cohort-study of patients with MM between 2015 and 2023 was conducted. Patients with an ICD-10th code C90.0 were included, and their administrative health records were extracted. The index date was defined as the time when the patient is diagnosed MM and they were followed until death, insurance discontinuation (patient loss), or the end of the observation period (31 December 2023), whichever occurred first. Patient demographics, disease subtype and comorbidities were assessed at index.
RESULTS: The study included 700 patients (median age: 64, Interquartile range [IQR] 16, Q1-Q3: 55-71). In the cohort 52.4% were female and 66.6% were mestizoes ethnicity. Common comorbidities included arterial hypertension (50.5%), chronic kidney disease (22.7%), and diabetes mellitus (15.7%). The average Charlson Comorbidity Index (CCI) score was 3 (IQR 3). 49.3% were in stage III at the International Stage System and 35.4% were in stage IIIA at the Durie-Salmon Staging System. 50.9% had an ECOG of 1, 82.6% experienced a skeletal-related event, and 41.7% underwent autologous transplantation (AT). At diagnosis, 52.3% had IgG kappa subtype. Translocation t14;16 (42.9%) was a common genetic alteration, with predominant karyotypes being 46xy (22.4%) and 46xx (18.1%). Differences between AT and non-AT recipients were noted; AT recipients were younger (mean age 56.4 vs. 67.5), female (56.8% vs. 49.3%) and had fewer comorbidities such as hypertension (40.4% vs. 57.8%), diabetes (8.2% vs. 21.8%) and a lower mean CCI score (2.5 vs. 4.6).
CONCLUSIONS: Patients with MM were elderly mestizoes, mainly had skeletal-related event and moderate mortality risk according to CCI. A large proportion were in late-stage disease, and less than half reported AT. Those who underwent AT were younger, female with proportionally fewer comorbidities and lower mortality risk.
METHODS: A retrospective, descriptive and cohort-study of patients with MM between 2015 and 2023 was conducted. Patients with an ICD-10th code C90.0 were included, and their administrative health records were extracted. The index date was defined as the time when the patient is diagnosed MM and they were followed until death, insurance discontinuation (patient loss), or the end of the observation period (31 December 2023), whichever occurred first. Patient demographics, disease subtype and comorbidities were assessed at index.
RESULTS: The study included 700 patients (median age: 64, Interquartile range [IQR] 16, Q1-Q3: 55-71). In the cohort 52.4% were female and 66.6% were mestizoes ethnicity. Common comorbidities included arterial hypertension (50.5%), chronic kidney disease (22.7%), and diabetes mellitus (15.7%). The average Charlson Comorbidity Index (CCI) score was 3 (IQR 3). 49.3% were in stage III at the International Stage System and 35.4% were in stage IIIA at the Durie-Salmon Staging System. 50.9% had an ECOG of 1, 82.6% experienced a skeletal-related event, and 41.7% underwent autologous transplantation (AT). At diagnosis, 52.3% had IgG kappa subtype. Translocation t14;16 (42.9%) was a common genetic alteration, with predominant karyotypes being 46xy (22.4%) and 46xx (18.1%). Differences between AT and non-AT recipients were noted; AT recipients were younger (mean age 56.4 vs. 67.5), female (56.8% vs. 49.3%) and had fewer comorbidities such as hypertension (40.4% vs. 57.8%), diabetes (8.2% vs. 21.8%) and a lower mean CCI score (2.5 vs. 4.6).
CONCLUSIONS: Patients with MM were elderly mestizoes, mainly had skeletal-related event and moderate mortality risk according to CCI. A large proportion were in late-stage disease, and less than half reported AT. Those who underwent AT were younger, female with proportionally fewer comorbidities and lower mortality risk.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH56
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
SDC: Oncology